Resverlogix Corp. · TSX:RVX
Resverlogix — Shareholder Meeting (June 2023)
39 slides from Resverlogix's shareholder meeting presentation, Jun 20, 2023
Slide 1: Annual General Meeting 2023
Annual General Meeting 2023 Management Update and Discussion
Slide 2: Overview
2 Overview 1. Apabetalone Review: An Advanced Epigenetic Drug 2. Commercial Potential 3. Current Life Science Industry 4. Post COVID-19 Conditions Trial Update 5. BETonMACE2 Planning 6. Funding Option Example
Slide 3: Apabetalone: A Thoroughly Characterized, De-risked, Phase 3 Asset
3 Apabetalone: A Thoroughly Characterized, De-risked, Phase 3 Asset with a Track Record of Safety and Efficacy Robust Detailed Over 40 4200+ patient- US FDA Intellectual proteomic & peer-reviewed years of FDA- Breakthrough Property transcriptomic publications reviewed safety Therapy Protection analy
Slide 4: Strong Synergy with SGLT2i & DPP4i
4 BETonMACE Clinical Result: Strong Synergy with MACE and Heart Failure Hospitalizations SGLT2i & DPP4i Placebo • Apabetalone demonstrated potential synergy with SGLT2 inhibitors & DPP4 inhibitors (next generation diabetes drugs) Hazard Ratio = 0.37 (0.22-0.62) p=0.0002 − Resverlogix has filed sever
Slide 5: Reduced MACE in CKD Patients
5 BETonMACE Clinical Result: Reduced MACE in MACE and Heart Failure Hospitalizations CKD Patients Placebo • In participants with chronic kidney disease (CKD), apabetalone was associated with fewer major adverse cardiac events (MACE) and fewer 50% Hazard heart failure hospitalizations (HHF) Reduction
Slide 6: Realizing the Untapped Potential of Epigenetics
6 Apabetalone: Realizing the Untapped Potential of Epigenetics DNA WITHOUT ALTERING DNA • Apabetalone regulates expression Apabetalone of disease-causing genes mRNA EPIGENETIC MECHANISM Pfizer & Moderna • Through inhibition of BET proteins, apabetalone acts at the level of COVID-19 gene transcriptio
Slide 7: Regulating Vascular Disease
7 Apabetalone: Regulating Vascular Disease Multiple Complement Vascular pathways System Inflammation contribute to the development and progression Epigenetic Reverse of vascular Coagulation Regulation disease Cholesterol Cascade by Apabetalone Transport Apabetalone counters the Many of the same dysr
Slide 8: Four Pillars: Therapeutic Product Development
8 Four Pillars: Therapeutic Product Development 1 2 3 Intellectual Property Regulatory Approval Commercialization & Academic Support Pathway Strategy & Capacity Financing • Multiple patents • Breakthrough Therapy • Expanded partnership • Industry-wide decrease • Coverage to 2041 Designation with EVE
Slide 9: Commercial Potential
RESVERLOGIX DD Commercial Potential ee,
Slide 10: Multiple Unaddressed Indications
10 Commercial Opportunity: Multiple Unaddressed Indications • Apabetalone addresses critical unmet need in high-risk patients with few available treatment options • Multiple benefits across expanded indications provides an unprecedented commercial opportunity Type 2 Diabetes Patients with Type 2 Dia
Slide 11: Targeting Massive Markets
11 Commercial Opportunity: Targeting Massive Markets $10,000 $8,936 $9,000 $8,614 $8,326 $8,250 $8,000 Gross Revenue (Millions of USD) $7,391 $7,000 $6,387 Projected $6,000 $5,476 $5,591 revenues for $5,000 $4,655 two priority $4,237 $3,916 indications $4,000 $3,257 (high-risk CVD $3,000 $2,673 & PC
Slide 12: A Potential Blockbuster
12 Commercial Opportunity Comparison: A Potential Blockbuster • With dramatic improvements in cardiac outcomes, a long exclusive runway, and no major competitors, apabetalone is a potential game changer in cardiovascular therapeutics • Expansion to multiple promising indications could provide furthe
Slide 13: Current Condition of the Life Sciences Industry
13 Current Condition of the Life Sciences Industry The Good, The Bad & The Ugly!
Slide 14: Pharma M&A was Down in 2022
14 Industry Perspective: Pharma M&A was Down in 2022 • 2022 was a difficult year for the financial Combined Value (2022): markets and for the pharmaceutical industry specifically 41% • Due to macroeconomic trends, and the over- US$158.5Bn capitalization of biotechnology companies in Decrease in Phar
Slide 15: Biotechnology – an Industry in Difficult Times
15 Biotechnology – an Industry in Difficult Times • The volume of biotech initial public offerings (IPOs) Price Drops of 2021 Biotech IPOs and the funds raised by these offerings declined in 50-59% 60-69% 70-79% 80-89% 90-99% 2022 and the first half of 2023 9 8 Year IPOs Funds Raised 14 14 2023* 7 $
Slide 16: Pharma is Motivated to Replace Expiring IP
16 2025 Upcoming Patent Cliff: Farxiga Pharma is Motivated AstraZeneca $0.73 Bn 2027 to Replace Expiring IP Benlysta GSK $0.95 Bn Invokana J&J $0.31 Bn Descovy Dovato • Between 2023-2030, almost all major Gilead 2026 GSK 2028 $1.40 Bn $3.63 Bn pharma companies will see patents Entresto Bridion Ibran
Slide 17: Pharma is Motivated to Replace Expiring IP
17 2025 Upcoming Patent Cliff: Farxiga Pharma is Motivated AstraZeneca $0.73 Bn 2027 to Replace Expiring IP Benlysta GSK $0.95 Bn Invokana J&J $0.31 Bn Descovy Dovato • Many of the drugs with expiring IP Gilead 2026 GSK 2028 $1.40 Bn $3.63 Bn are indicated for conditions in which Entresto Bridion Ib
Slide 18: Post COVID-19 Conditions Trial
18 Post COVID-19 Conditions Trial Addressing the evolving challenges of the global pandemic
Slide 19: Apabetalone and Disease Progression
19 COVID-19: Apabetalone and Disease Progression Hyper-inflammatory Post COVID-19 Early Infection Pulmonary Phase Phase Conditions Asymptomatic Mild to Moderate Symptoms Severe to Critical Symptoms Ongoing Symptoms (~35%) (~45%) (~20%) (10-50%) Viral Growth and Activity Host Inflammatory Response Po
Slide 20: Apabetalone and Disease Progression
20 COVID-19: Apabetalone and Disease Progression Hyper-inflammatory Post COVID-19 Early Infection Pulmonary Phase Phase Conditions Asymptomatic Mild to Moderate Symptoms Severe to Critical Symptoms Ongoing Symptoms (~35%) (~45%) (~20%) (10-50%) Existing Treatment Options Apabetalone Limited Viral Gr
Slide 21: Increased Burden of Multiple Cardiovascular Events
21 Post COVID-19 Cardiovascular Outcomes: Increased Burden of Multiple Cardiovascular Events COVID-19 Survivors Non-Infected Control MACE (Major Adverse Cardiac Event) 1.5x Risk People who contract Heart Attack COVID-19 have a 50%- 1.6x Risk 70% greater risk of severe cardiac events in the first Str
Slide 22: A Growing Body of Literature Supports Long-Term Risks
22 Post COVID-19 Cardiovascular Outcomes: A Growing Body of Literature Supports Long-Term Risks Numerous high-quality peer-reviewed publications have independently confirmed increased risk of negative cardiovascular outcomes following COVID-19 infection
Slide 23: Scientific Advisory Board
23 Post COVID-19 Conditions: Scientific Advisory Board • A team of highly engaged, experienced, and respected COVID-19 clinical trial investigators • Infectious Disease, Critical and Emergency Care Specialists
Slide 24: BETonMACE2 Clinical Program
24 BETonMACE2 Clinical Program A registration-enabling clinical study of apabetalone with FDA Breakthrough Therapy Designation
Slide 25: Accelerated Development with Interim Analyses
25 Clinical Trial Timelines: Accelerated Development with Interim Analyses Jun-23 Nov-23 May-24 Nov-24 May-25 Nov-25 Planning & Documents Finalization BETonMACE2 Start-up First Patient In Screening & Recruitment Last Patient In Treatment & Follow-up Interim Analysis (At 300 Events) Planning & Docume
Slide 26: EVERSANA: Flexibility in Commercialization
26 EVERSANA™: Flexibility in Commercialization 100% of the Top 25 Bio-pharma Companies 570 500 MDs, RNs, Life Science PharmDs Clients 7,000 80 100 Countries Employees Therapeutic Served Areas 25 25 Patient Locations Service Programs 150 Brands We partnered with EVERSANA™ to support the development o
Slide 27: Recent Advancements
27 Clinical Programs: Recent Advancements We are a global leader in the development of epigenetic therapies for the treatment of chronic disease
Slide 28: Funding Option Example
28 Funding Option Example
Slide 29: Corporate Strategy
Corporate Strategy Value Creation Strategies for 2023 - Divergence!
Slide 30: Corporate Structure – Two Major Assets
Corporate Structure – Two Major Assets Formed in 2013 – Structured for Value Creation $75MM raised to date in Zenith Capital Corp addition to securing an (Alberta, reporting $85MM in clinical trial issuer) and drug expenses. 100% 100% $XXX-MM valuation for 50% • 3-6% Ascending Royalty $XXX to XXX-MM
Slide 31: Corporate Structure – Two Major Assets
Corporate Structure – Two Major Assets Formed in 2013 – Structured for Value Creation $75MM raised to date in Zenith Capital Corp addition to securing an (Alberta, reporting $85MM in clinical trial issuer) and drug expenses. 100% 100% In discussions $XXX-MM valuation for 50% • 3-6% Ascending Royalty
Slide 32: Corporate Structure – Two Major Assets
Corporate Structure – Two Major Assets Formed in 2013 – Structured for Value Creation $75MM raised to date in Zenith Capital Corp addition to securing an (Alberta, reporting $85MM in clinical trial issuer) and drug expenses. 100% 100% In discussions, term sheet details requested $XXX-MM valuation fo
Slide 33: Near CR with ZEN-3694 in Nut Midline Carcinoma Patient
Near CR with ZEN-3694 in Nut Midline Carcinoma Patient 10/5/22 12/9/22 3/7/23 • Progressing on bone and lung lesions prior to treatment • 12/18/22 : Single agent ZEN-3694 treatment started at 48mg/qd • Dose interruption due to diarrhea in Cycle 1 • ~2/2/23 : ZEN-3694 dose increased to 48mg BID – is
Slide 34: Thoracic NUT Carcinoma Patient on compassionate use ZEN-3694
Thoracic NUT Carcinoma Patient on compassionate use ZEN-3694 Clinical History: PDL1+, Thoracic NUT carcinoma • Started cis/etop 10/4/22 12/01/22 • Added ZEN-3694 on cycle 2 (48mg) 09/18/22 Abdominal 10/25/22 Lung lesion:160mm • ZEN increased to 60 5:2 11/15/22 lesion:70.45mm • Completed 6 cycles of
Slide 35: Inhouse Clinical Trial Result - 73% decrease in Lung Lesions
Inhouse Clinical Trial Result - 73% decrease in Lung Lesions (Triple Negative Breast Cancer that metastasized to the Lungs) 12 10 Target 1: lung rt upper lobe 8 PR Tumor Size (mm) 8 weeks = 54% ↓ Non-target lt lung lesion - significant ↓ Subcutaneous lesion - disappeared 6 4 PR 16 weeks = 71% ↓ 2 PR
Slide 36: Inhouse Clinical Trial Result - 92% decrease in Liver Lesions
Inhouse Clinical Trial Result - 92% decrease in Liver Lesions (Triple Negative Breast Cancer that metastasized to the Liver) START ZEN-3694 + TALA 35 30 Target 1: Supraclavicular rt. lymph node 25 PR Target 2: Liver segment VIII 8 weeks = 65% ↓ Tumor Size (mm) 17 weeks = 92% ↓ 20 Target 3: Liver seg
Slide 37: Exceptional Responders in Triple Combo Clinical Trial
Exceptional Responders in Triple Combo Clinical Trial (Prostate Cancer mCRPC Metastasized to Bone and Liver) CohortCohort B patient CR: 100% Disappearance of bone lesions Cohort A patient PR: 60% decrease in liver lesions Post cycle 3 Baseline Zenith Epigenetics Overview | 37
Slide 38: Investigator Sponsored and National Cancer Institute Trials
Investigator Sponsored and National Cancer Institute Trials (13 additional exterior run trials paid for by our collaborators) Advance to registration enabling studies in multiple additional indications and combinations upon proof-of-concept dat 1H 2021 2H 2021 1H2022 2H 2022 1H 2023 2H 2023 1H 2024
Slide 39: Contact
39 Contact Donald McCaffrey, President & CEO Email: don@resverlogix.com Phone: 587-390-7888 Website: www.resverlogix.com